Industry supported symposia are scientific programs developed for educational purposes. All symposia are in compliance with Accreditation Council for Pharmacy Education (ACPE) criteria for planning and implementation. Each provide 1.5 contact hours of ACPE credit. Meals or snack items may be provided at the start of each event. Room capacities at symposia are limited and entrance is granted on a first-come, first-served basis.
Psychiatric and neurologic pharmacists are actively involved in the care of patients with long-standing psychiatric illness, many of whom receive first and second-generation antipsychotic medications. Specialty neurologic and psychiatric pharmacists have been shown to assess abnormal movements at a skill level comparable to trained physicians and are ideally positioned to assist in the differentiation of extrapyramidal symptoms (EPS) and identify patients at risk of developing or having already developed tardive dyskinesia (TD). They also may guide optimal medication selection; assist with procurement of appropriate agents; oversee dosing, titration, and adjustments that may be needed due to drug interactions; and screen for adverse effects from treatments. Using case-based scenarios and interactive audience response technology, CPNP attendees will review new data with clinical experts to ensure they are current with their assessment techniques and knowledgeable about new treatment options. Learn more.
Steve Stoner, PharmD, BCPP (Chair/Moderator) Clinical Professor and Chair University of Missouri at Kansas City School of Pharmacy Kansas City, MO |
|
Jason P. Caplan, MD, FAPM St. Joseph’s Hospital and Medical Center Phoenix, Arizona |
|
Sabrina Livezey, PharmD Vanderbilt Specialty Pharmacy Services Vanderbilt University Medical Center Nashville, Tennessee |
In support of improving patient care, Creative Educational Concepts, Inc. is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Pharmacy (ACPE)
This application-based activity is approved for 1.5 contact hours (0.15 CEUs) of continuing pharmacy education credit. Pharmacy credit will be reported directly to the National Association of Boards of Pharmacy (NABP) CPE Monitor electronic CE tracking system.
Creative Educational Concepts, Inc.
Neurocrine
Schizophrenia is a chronic, complex, and disabling mental health disorder that affects between 0.6% to 1.9% of the US population. The goals of therapy should be to limit or eliminate symptoms, reduce side effects of medication, maximize quality of life, and assist patients in reaching life-goals. Nonadherence to pharmacotherapy in patients with schizophrenia is a common and costly problem, but long-acting injectable (LAI) antipsychotics have changed the treatment landscape for these patients. LAI antipsychotic medications improve adherence to therapy by maintaining a therapeutic drug concentration in the plasma. This symposium will focus on the pharmacist’s role in examining emerging treatment options for schizophrenia, and how these agents can increase adherence to improve outcomes. The pharmacist’s role in encouraging appropriate treatment selection, counseling to improve adherence, and managing any potential drug-to-drug interactions will be reviewed.
Devon Sherwood PharmD, BCPP
Assistant Professor
College of Pharmacy
University of New England
Portland, Maine
Clinical Psychopharmacology Specialist
Spring Harbor Hospital
Westbrook, Maine
Pharmacy Times Continuing Education™ is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 1.5 contact hours (0.15 CEUs) under the ACPE universal activity number 0290-0000-18-031-L01-P. The activity is available for CE credit through April 23, 2018.
Pharmacy Times Continuing Education
Indivior
Long-acting injectable (LAI) formulations for schizophrenia are important alternatives to oral antipsychotics and have been shown to be effective at preventing relapse in a population known to have high rates of relapse and rehospitalization. Additionally, use of these agents earlier in the disease course has been shown to positively impact long-term prognosis. While current guidelines recognize LAI antipsychotics as a treatment option, their use is under-utilized. Many clinician, patient and care system barriers exist which limit effective and consistent use of LAIs in patients that may benefit from their use. Additionally, clinicians can find it a challenge to understand the pharmacokinetic and pharmacodynamic considerations of the individual agents and appropriately initiate and adjust LAI antipsychotic dosing for individual patients. Through didactic and case-based presentations, this symposium will present the most up-to-date science on the differences in available LAI antipsychotics and the necessary considerations to select the appropriate agent for each patient, thus improving outcomes.
Roger W. Sommi, PharmD, BCPP, FCCP
Professor of Pharmacy Practice and Psychiatry
Associate Dean, UMKC School of Pharmacy at MU
University of Missouri – Kansas City School of Pharmacy
Kansas City, MO
Postgraduate Healthcare Education, Inc. is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This knowledge-based activity is approved for 1.0 contact hour (0.1 CEU).
Postgraduate Healthcare Education, Inc.
Alkermes